|Treatments:||Biologic therapy||Hospital:||Tohoku University|
Patients: This Phase II trial involved a total of 75 patients with advanced non-small-cell lung cancer. There were 30 men and 45 women. Subtypes included adenocarcinoma (64 patients) and non-adenocarcinoma (11 patients). None of the patients had previous chemotherapy.
Treatment: The treatment consisted of biological therapy – Iressa (Gefitinib) an oral tyrosine kinase inhibitor of the epidermal growth factor receptor.
Toxicity: Grade 3 toxicities included elevation of a hepatic enzyme.
Results: The median overall survival was not reported.
Correspondance: Akira Inoue, MD